Tanshinone I improves renal fibrosis by promoting gluconeogenesis through upregulation of peroxisome proliferator-activated receptor-γ coactivator 1α

被引:0
作者
Bai, Yanfang [1 ,2 ,3 ]
Wen, Hui [1 ,2 ,3 ]
Lin, Junyan [4 ]
Liu, Xinying [5 ]
Yu, Hua [6 ]
Wu, Ming [1 ,2 ,3 ]
Wang, Ling [7 ]
Chen, Dongping [1 ,2 ,3 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Nephrol, 528 Zhangheng Rd, Shanghai 201203, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, TCM Inst Kidney Dis, Shanghai, Peoples R China
[3] Minist Educ, Key Lab Liver & Kidney Dis, Shanghai Key Lab Tradit Chinese Clin Med, Shanghai, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai Peoples Hosp 10, Dept Rheumatol, Shanghai, Peoples R China
[6] Shanghai Zhabei Dist Cent Hosp, Shanghai, Peoples R China
[7] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nephrol, 301 Yanchangzhong Rd, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
Tanshinone I; gluconeogenesis; PGC1; alpha; renal fibrosis; chronic kidney disease; CHRONIC KIDNEY-DISEASE; CELL-CYCLE ARREST; HEPATIC GLUCONEOGENESIS; MECHANISMS; INSULIN; DAMAGE; LIVER; PGC-1; MICE;
D O I
10.1080/0886022X.2024.2433710
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundRenal fibrosis, a hallmark of chronic kidney disease, is closely associated with dysregulated gluconeogenesis. Tanshinone I (Tan I), a bioactive compound derived from the traditional Chinese medicine Danshen, exhibits antifibrotic and anti-inflammatory properties. However, its effects on gluconeogenesis and the mechanisms through which it alleviates renal fibrosis remain unclear. This study aimed to investigate whether Tan I promotes gluconeogenesis and mitigates renal fibrosis.MethodsBoth in vivo and in vitro experiments were conducted. A unilateral ureteral obstruction (UUO) mouse model was used. Masson's trichrome, HE, and immunofluorescence staining, along with Western blotting, were employed. Lactate concentrations and a pyruvate tolerance test were conducted to assess glucose metabolism. In vitro, HK2 cells and primary renal tubular cells were treated with transforming growth factor-beta (TGF beta) to induce fibrosis, and the effects of Tan I on glucose and lactate levels were examined.ResultsIn the UUO model, Tan I reduced fibrosis, decreased lactate accumulation, and modulated fibrosis markers while upregulating gluconeogenesis markers. Tanshinone I restored impaired renal gluconeogenesis, as evidenced by increased pyruvate levels. In vitro, Tan I inhibited fibrosis, reduced lactate levels, and increased glucose levels in cell supernatants. It also restored gluconeogenesis protein expression and decreased fibrotic protein levels. Peroxisome proliferator-activated receptor-gamma coactivator (PGC1 alpha) expression was downregulated in UUO and TGF beta-stimulated models, and Tan I reversed this downregulation. Inhibition of PGC1 alpha in TGF beta-stimulated cells counteracted the antifibrotic and gluconeogenesis-promoting effects of Tan I.ConclusionsTanshinone I ameliorated renal fibrosis by enhancing gluconeogenesis through upregulation of PGC1 alpha.
引用
收藏
页数:12
相关论文
共 48 条
  • [1] PGC-1a Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response
    Abu Shelbayeh, Othman
    Arroum, Tasnim
    Morris, Silke
    Busch, Karin B.
    [J]. ANTIOXIDANTS, 2023, 12 (05)
  • [2] Integrated analysis reveals crosstalk between pyroptosis and immune regulation in renal fibrosis
    Bai, Fengxia
    Han, Longchao
    Yang, Jifeng
    Liu, Yuxiu
    Li, Xiangmeng
    Wang, Yaqin
    Jiang, Ruijian
    Zeng, Zhaomu
    Gao, Yan
    Zhang, Haisong
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment
    Bi, Zhangyang
    Wang, Yayun
    Zhang, Wei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [4] Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study
    Bikbov, Boris
    Perico, Norberto
    Remuzzi, Giuseppe
    [J]. NEPHRON, 2018, 139 (04) : 313 - 318
  • [5] PGC-1α in Disease: Recent Renal Insights into a Versatile Metabolic Regulator
    Chambers, Joseph M.
    Wingert, Rebecca A.
    [J]. CELLS, 2020, 9 (10)
  • [6] Cardiac Fibroblast-Specific Knockout of PGC-1α Accelerates AngII-Induced Cardiac Remodeling
    Chen, Hong-jin
    Pan, Xiao-xi
    Ding, Li-li-qiang
    Ruan, Cheng-chao
    Gao, Ping-jin
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [7] PGC-1 as a Pivotal Factor in Lipid and Metabolic Regulation
    Cheng, Ching-Feng
    Ku, Hui-Chen
    Lin, Heng
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [8] Gluconeogenesis in the kidney: in health and in chronic kidney disease
    Dalga, Delal
    Verissimo, Thomas
    de Seigneux, Sophie
    [J]. CLINICAL KIDNEY JOURNAL, 2023, 16 (08) : 1249 - 1257
  • [9] Overview of the cellular and molecular basis of kidney fibrosis
    Eddy, Allison A.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2014, 4 (01) : 2 - 8
  • [10] Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries
    Faivre, Anna
    Verissimo, Thomas
    Auwerx, Hannah
    Legouis, David
    de Seigneux, Sophie
    [J]. FRONTIERS IN MEDICINE, 2021, 8